Trade GlycoMimetics - GLYC CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
| Spread | 0.0180 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
GlycoMimetics Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
| Prev. Close* | 1.916 |
| Open* | 1.996 |
| 1-Year Change* | 41.9% |
| Day's Range* | 1.796 - 2.036 |
| 52 wk Range | 1.11-4.16 |
| Average Volume (10 days) | 401.44K |
| Average Volume (3 months) | 4.69M |
| Market Cap | 197.04M |
| P/E Ratio | -100.00K |
| Shares Outstanding | 64.39M |
| Revenue | N/A |
| EPS | -0.64 |
| Dividend (Yield %) | N/A |
| Beta | 2.19 |
| Next Earnings Date | Mar 27, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 22, 2024 | 1.7960 | -0.2000 | -10.02% | 1.9960 | 2.0360 | 1.7960 |
| Apr 19, 2024 | 1.9160 | -0.2100 | -9.88% | 2.1260 | 2.1460 | 1.8560 |
| Apr 18, 2024 | 2.1460 | -0.1400 | -6.12% | 2.2860 | 2.2960 | 2.1460 |
| Apr 17, 2024 | 2.2760 | 0.1500 | 7.06% | 2.1260 | 2.3760 | 2.1260 |
| Apr 16, 2024 | 2.1460 | -0.0900 | -4.03% | 2.2360 | 2.3060 | 2.1360 |
| Apr 15, 2024 | 2.2460 | -0.1500 | -6.26% | 2.3960 | 2.4460 | 2.2260 |
| Apr 12, 2024 | 2.3760 | -0.1100 | -4.42% | 2.4860 | 2.5160 | 2.3060 |
| Apr 11, 2024 | 2.4960 | 0.0000 | 0.00% | 2.4960 | 2.5260 | 2.4760 |
| Apr 10, 2024 | 2.4360 | -0.2400 | -8.97% | 2.6760 | 2.6760 | 2.4160 |
| Apr 9, 2024 | 2.6660 | 0.0600 | 2.30% | 2.6060 | 2.6960 | 2.5860 |
| Apr 8, 2024 | 2.5760 | -0.2100 | -7.54% | 2.7860 | 2.7860 | 2.5560 |
| Apr 5, 2024 | 2.7360 | -0.0700 | -2.49% | 2.8060 | 2.8060 | 2.6460 |
| Apr 4, 2024 | 2.6960 | -0.0800 | -2.88% | 2.7760 | 2.8460 | 2.6760 |
| Apr 3, 2024 | 2.7560 | -0.2100 | -7.08% | 2.9660 | 2.9960 | 2.7160 |
| Apr 2, 2024 | 2.9460 | -0.0500 | -1.67% | 2.9960 | 3.1260 | 2.8960 |
| Apr 1, 2024 | 3.0260 | 0.0100 | 0.33% | 3.0160 | 3.1060 | 2.9860 |
| Mar 28, 2024 | 3.0060 | -0.0400 | -1.31% | 3.0460 | 3.0760 | 2.8960 |
| Mar 27, 2024 | 3.1560 | 0.2600 | 8.98% | 2.8960 | 3.1560 | 2.7460 |
| Mar 26, 2024 | 2.8460 | 0.0000 | 0.00% | 2.8460 | 2.8760 | 2.7760 |
| Mar 25, 2024 | 2.8260 | -0.1000 | -3.42% | 2.9260 | 3.0060 | 2.7660 |
GlycoMimetics Events
| Time (UTC) | Country | Event |
|---|---|---|
| Wednesday, May 1, 2024 | ||
| Time (UTC) 12:30 | Country US
| Event Q1 2024 GlycoMimetics Inc Earnings Release Q1 2024 GlycoMimetics Inc Earnings ReleaseForecast -Previous - |
| Time (UTC) 13:00 | Country US
| Event GlycoMimetics Inc Annual Shareholders Meeting GlycoMimetics Inc Annual Shareholders MeetingForecast -Previous - |
| Friday, May 17, 2024 | ||
| Time (UTC) 13:00 | Country US
| Event GlycoMimetics Inc Annual Shareholders Meeting GlycoMimetics Inc Annual Shareholders MeetingForecast -Previous - |
| Wednesday, July 31, 2024 | ||
| Time (UTC) 12:30 | Country US
| Event Q2 2024 GlycoMimetics Inc Earnings Release Q2 2024 GlycoMimetics Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total revenue | 0.075 | 1.15977 | 10.1629 | 0 | 0 |
| Revenue | 0.075 | 1.15977 | 10.1629 | 0 | 0 |
| Total Operating Expense | 47.4783 | 64.607 | 61.6723 | 61.3893 | 51.5048 |
| Selling/General/Admin. Expenses, Total | 19.0874 | 17.1154 | 16.7431 | 14.36 | 11.413 |
| Research & Development | 28.3909 | 47.4916 | 44.9292 | 47.0293 | 40.0918 |
| Operating Income | -47.4033 | -63.4472 | -51.5094 | -61.3893 | -51.5048 |
| Interest Income (Expense), Net Non-Operating | 0.71452 | 0.01977 | 0.48249 | 3.49739 | 3.23119 |
| Net Income Before Taxes | -46.6888 | -63.4274 | -51.0269 | -57.8919 | -48.2736 |
| Net Income After Taxes | -46.6888 | -63.4274 | -51.0269 | -57.8919 | -48.2736 |
| Net Income Before Extra. Items | -46.6888 | -63.4274 | -51.0269 | -57.8919 | -48.2736 |
| Net Income | -46.6888 | -63.4274 | -51.0269 | -57.8919 | -48.2736 |
| Income Available to Common Excl. Extra. Items | -46.6888 | -63.4274 | -51.0269 | -57.8919 | -48.2736 |
| Income Available to Common Incl. Extra. Items | -46.6888 | -63.4274 | -51.0269 | -57.8919 | -48.2736 |
| Diluted Net Income | -46.6888 | -63.4274 | -51.0269 | -57.8919 | -48.2736 |
| Diluted Weighted Average Shares | 52.5312 | 51.4532 | 45.7211 | 43.2548 | 41.0446 |
| Diluted EPS Excluding Extraordinary Items | -0.88878 | -1.23272 | -1.11605 | -1.33839 | -1.17613 |
| Diluted Normalized EPS | -0.88878 | -1.23272 | -1.11605 | -1.33839 | -1.17613 |
| Total Extraordinary Items |
| Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0.075 |
| Revenue | 0 | 0 | 0 | 0.075 | |
| Total Operating Expense | 8.92995 | 10.941 | 10.6226 | 8.76744 | 13.4282 |
| Selling/General/Admin. Expenses, Total | 4.85724 | 5.52231 | 4.7318 | 3.84458 | 5.45488 |
| Research & Development | 4.07271 | 5.41871 | 5.89082 | 4.92286 | 7.97328 |
| Operating Income | -8.92995 | -10.941 | -10.6226 | -8.76744 | -13.3532 |
| Interest Income (Expense), Net Non-Operating | 0.67103 | 0.58167 | 0.37827 | 0.2436 | 0.08559 |
| Net Income Before Taxes | -8.25891 | -10.3594 | -10.2444 | -8.52384 | -13.2676 |
| Net Income After Taxes | -8.25891 | -10.3594 | -10.2444 | -8.52384 | -13.2676 |
| Net Income Before Extra. Items | -8.25891 | -10.3594 | -10.2444 | -8.52384 | -13.2676 |
| Net Income | -8.25891 | -10.3594 | -10.2444 | -8.52384 | -13.2676 |
| Income Available to Common Excl. Extra. Items | -8.25891 | -10.3594 | -10.2444 | -8.52384 | -13.2676 |
| Income Available to Common Incl. Extra. Items | -8.25891 | -10.3594 | -10.2444 | -8.52384 | -13.2676 |
| Diluted Net Income | -8.25891 | -10.3594 | -10.2444 | -8.52384 | -13.2676 |
| Diluted Weighted Average Shares | 64.2762 | 60.3501 | 52.962 | 52.4239 | 52.4073 |
| Diluted EPS Excluding Extraordinary Items | -0.12849 | -0.17165 | -0.19343 | -0.16259 | -0.25316 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -0.12849 | -0.17165 | -0.19343 | -0.16259 | -0.25316 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total Current Assets | 50.7147 | 90.7887 | 138.273 | 162.528 | 212.269 |
| Cash and Short Term Investments | 47.8706 | 90.2549 | 137.035 | 158.201 | 209.918 |
| Cash & Equivalents | 47.8706 | 90.2549 | 137.035 | 158.201 | 209.918 |
| Short Term Investments | |||||
| Total Receivables, Net | 0.14402 | 0.00135 | 0.00215 | 0.18595 | 0.41312 |
| Prepaid Expenses | 2.70007 | 0.53246 | 1.23618 | 4.14037 | 1.9384 |
| Total Assets | 51.8106 | 94.3466 | 142.832 | 167.97 | 214.839 |
| Property/Plant/Equipment, Total - Net | 0.99356 | 1.94503 | 2.9459 | 3.82899 | 0.95723 |
| Property/Plant/Equipment, Total - Gross | 3.38018 | 4.26792 | 5.0782 | 5.69053 | 2.54087 |
| Accumulated Depreciation, Total | -2.38662 | -2.3229 | -2.1323 | -1.86155 | -1.58364 |
| Other Long Term Assets, Total | 0.10232 | 1.61293 | 1.61293 | 1.61293 | 1.61293 |
| Total Current Liabilities | 8.88075 | 11.8244 | 12.4284 | 10.9506 | 8.76315 |
| Accounts Payable | 0.97019 | 2.10762 | 2.08994 | 1.43566 | 2.66358 |
| Accrued Expenses | 7.91056 | 9.71678 | 10.3384 | 9.51492 | 6.0008 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 0.09877 | ||||
| Total Liabilities | 8.88075 | 12.743 | 14.6127 | 13.7691 | 9.37478 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 0 | 0.91861 | 2.18434 | 2.81852 | 0.61162 |
| Total Equity | 42.9298 | 81.6037 | 128.219 | 154.201 | 205.464 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | |||
| Common Stock | 0.05438 | 0.05231 | 0.04902 | 0.04347 | 0.04316 |
| Additional Paid-In Capital | 462.461 | 454.448 | 437.64 | 412.6 | 405.972 |
| Retained Earnings (Accumulated Deficit) | -419.586 | -372.897 | -309.47 | -258.443 | -200.551 |
| Total Liabilities & Shareholders’ Equity | 51.8106 | 94.3466 | 142.832 | 167.97 | 214.839 |
| Total Common Shares Outstanding | 54.3778 | 52.3139 | 49.0176 | 43.4669 | 43.1608 |
| Total Preferred Shares Outstanding |
| Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 52.0101 | 60.3688 | 68.0865 | 50.7147 | 53.8482 |
| Cash and Short Term Investments | 49.4076 | 58.0371 | 65.0023 | 47.8706 | 51.6248 |
| Cash & Equivalents | 49.4076 | 58.0371 | 65.0023 | 47.8706 | 51.6248 |
| Total Receivables, Net | 0.18895 | 0.21537 | 0.23411 | 0.14402 | 0.09033 |
| Prepaid Expenses | 2.4135 | 2.11639 | 2.85008 | 2.70007 | 2.13309 |
| Total Assets | 53.2007 | 61.8215 | 68.9217 | 51.8106 | 55.9614 |
| Property/Plant/Equipment, Total - Net | 1.08829 | 1.35036 | 0.7328 | 0.99356 | 1.25313 |
| Property/Plant/Equipment, Total - Gross | 3.59843 | 3.81775 | 3.16326 | 3.38018 | 3.59403 |
| Accumulated Depreciation, Total | -2.51014 | -2.46739 | -2.43045 | -2.38662 | -2.3409 |
| Other Long Term Assets, Total | 0.10232 | 0.10232 | 0.10232 | 0.10232 | 0.86012 |
| Total Current Liabilities | 6.39088 | 6.572 | 6.74021 | 8.88075 | 7.74825 |
| Accounts Payable | 0.32989 | 0.24149 | 0.48015 | 0.97019 | 0.85213 |
| Accrued Expenses | 6.061 | 6.33052 | 6.26006 | 7.91056 | 6.89613 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 6.65301 | 7.02078 | 6.74021 | 8.88075 | 7.84386 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 0.26213 | 0.44878 | 0 | 0.09561 | |
| Total Equity | 46.5477 | 54.8007 | 62.1814 | 42.9298 | 48.1176 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
| Common Stock | 0.06437 | 0.06431 | 0.06425 | 0.05438 | 0.05242 |
| Additional Paid-In Capital | 493.89 | 492.94 | 492.062 | 462.461 | 457.407 |
| Retained Earnings (Accumulated Deficit) | -447.407 | -438.204 | -429.945 | -419.586 | -409.341 |
| Total Liabilities & Shareholders’ Equity | 53.2007 | 61.8215 | 68.9217 | 51.8106 | 55.9614 |
| Total Common Shares Outstanding | 64.3688 | 64.3133 | 64.2452 | 54.3778 | 52.4239 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -46.6888 | -63.4274 | -51.0269 | -57.8919 | -48.2736 |
| Cash From Operating Activities | -46.4575 | -57.4895 | -39.2419 | -51.9841 | -43.3311 |
| Cash From Operating Activities | 0.20715 | 0.2646 | 0.27075 | 0.27923 | 0.27512 |
| Non-Cash Items | 4.68609 | 6.8385 | 7.5826 | 6.83516 | 4.58727 |
| Cash Taxes Paid | |||||
| Changes in Working Capital | -4.66192 | -1.16519 | 3.93162 | -1.20662 | 0.08011 |
| Cash From Investing Activities | -0.08419 | -0.01494 | -0.06851 | -0.14493 | -0.12562 |
| Capital Expenditures | -0.08419 | -0.01494 | -0.06851 | -0.14493 | -0.12562 |
| Cash From Financing Activities | 4.15741 | 10.7243 | 18.144 | 0.41291 | 129.45 |
| Issuance (Retirement) of Stock, Net | 4.15741 | 10.7243 | 18.144 | 0.41291 | 129.45 |
| Net Change in Cash | -42.3843 | -46.7801 | -21.1664 | -51.7161 | 85.9929 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -10.3594 | -46.6888 | -36.4445 | -27.9206 | -14.653 |
| Cash From Operating Activities | -11.6069 | -46.4575 | -38.5459 | -29.9288 | -13.6981 |
| Cash From Operating Activities | 0.04384 | 0.20715 | 0.16143 | 0.11408 | 0.05931 |
| Non-Cash Items | 1.0893 | 4.68609 | 3.57304 | 2.45038 | 1.27946 |
| Changes in Working Capital | -2.38065 | -4.66192 | -5.83594 | -4.57266 | -0.38387 |
| Cash From Investing Activities | -0.0022 | -0.08419 | -0.08419 | -0.08171 | -0.04052 |
| Capital Expenditures | -0.0022 | -0.08419 | -0.08419 | -0.08171 | -0.04052 |
| Cash From Financing Activities | 28.7408 | 4.15741 | 0 | 0 | 0 |
| Issuance (Retirement) of Stock, Net | 28.7408 | 4.15741 | 0 | 0 | 0 |
| Net Change in Cash | 17.1317 | -42.3843 | -38.6301 | -30.0105 | -13.7387 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
GlycoMimetics Company profile
About GlycoMimetics Inc
GlycoMimetics, Inc. is a clinical-stage biotechnology company. The Company is focused on discovery and development of novel glycomimetic. Its drug candidates include Uproleselan, GMI-1359, Rivipansel, GMI-1687, and Galectin Antagonists. Its Uproleselan a specific E-selectin inhibitor, to be used in combination with chemotherapy to treat patients with acute myeloid leukemia (AML), a life-threatening hematologic cancer, and potentially other hematologic cancers. The GMI-1359 targets E-selectin and a chemokine receptor. Its Rivipansel is a glycomimetic drug candidate that act as , a pan-selectin antagonist for treatment of vaso-occlusive crisis. It has designed antagonist of E-selectin, GMI-1687, that is suitable for subcutaneous administration. Galectin Antagonists includes Galectin-3, which is a carbohydrate-binding protein.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, GlycoMimetics Inc revenues decreased 89% to $1.2M. Net loss increased 24% to $63.4M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research & Development Expenses increase of 8% to $45.3M (expense), Interest income decrease of 96% to $20K (income).
Equity composition
Common Stock, $0.001 Par, 100M Auth shares, 17,555,497 issd,. Insiders Owns approx. 10.08%.
| Industry: | Bio Therapeutic Drugs |
9708 Medical Center Drive
ROCKVILLE
MARYLAND 20850
US
Income Statement
- Annual
- Quarterly
News
Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024
US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024
Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024
US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024
How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024
A way forward: a roundup of recent central bank decisions
Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.
12:47, 22 March 2024
Bank of Japan Preview: will the BOJ end negative interest rates?
The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.
08:44, 18 March 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com